Peptides
Ovagen
Also called Ovagen
Ovagen is marketed for liver and digestive support, especially when people want to recover from illness or reduce the impact of medicines and other exposures. The hope is better function and wellbeing. A liver-focused product name and inventor-reported experiments do not establish that it reverses liver disease or makes a harmful exposure safe.
Dosage & duration
Supplier’s oral capsule directions
Peptides1 Ovagen product
Reported use · unapproved regimen- Dose
- 1–2 capsules per administration
- How often
- 1–2 times daily with meals
- How long
- 10–30 days
For that capsule product only; active composition and fill weight must remain distinct. Not a validated liver-disease course.
Sources: 2
The supplier’s repeat-course suggestion is not proof that periodic use protects the liver. No oral-to-injection conversion is established.
Why people consider Ovagen
Liver recovery and digestive comfort
-
Feeling better day to day
Readers may hope for a better appetite, less fatigue or less discomfort.
-
Liver support
Others are concerned about recovery after illness, medicines or other exposures.
Why do people consider Ovagen?
The appeal is broad liver and digestive resilience. But improved appetite or less fatigue is not proof of restored liver tissue, and an abnormal liver test cannot be explained by a generic supplement category.
What does the patent establish?
It identifies the peptide and reports the inventors’ experiments and use examples. A patent is not independent proof of a clinical benefit. Its existence should not turn a liver-regeneration claim into a promised result.
How does it differ from Livagen?
Ovagen and Livagen are different sequences sold for overlapping goals. There is no verified head-to-head result here establishing a better option or added protection when combined. Keep their product amounts separate.
Practical interpretation
The dose box describes a named capsule product. It does not establish an injection course or justify continuing an exposure that may be harming the liver. Persistent symptoms or abnormal tests deserve diagnosis and a cause-specific plan.
Model details: Ovagen · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Legacy 4.08 h remains an assumption; the patent has no verified plasma PK row used here.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 4.08 hours
- Absorption half-life assumed
- 1.02 hours
- Reference amount for the relative scale
- 1 mg
- Absorption half-life is assumed to be one quarter of the slower timescale (1.02 h); it is not a measured absorption parameter.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Ovagen is also a veterinaryFSH product name; that is not EDL peptide evidence.
- Animal kidney outcomes and small patent-use examples cannot calibrate human blood concentrations.
- Ovagen/EDL patent WO2007139430A1
Legacy 4.08 h remains an assumption; the patent has no verified plasma PK row used here.
ovagen-relative-timing-2026-10 · version 1
Common questions
Does Ovagen detox the liver?
Detox is too broad to be a measurable treatment claim. The reviewed patent and product directions do not establish removal of a specific toxin or reversal of liver disease.
Can I use the capsule milligrams for an injection?
No. Capsule fill, active composition and route are different quantities, and equivalence has not been established.
Sources Labels, studies and notes behind this guide
Catalog evidence: Animal or laboratory research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Main interests
- Fatigue or digestive discomfort does not identify liver disease.
- Compared with Livagen
- Similar goals do not establish equivalent amounts.
- Product course
- A capsule label cannot set the amount for a research injection.
- 1. Ovagen peptide patent WO2007139430A1
Primary patent inspected: EDL identity and inventor-reported experiments/use examples, not independent clinical validation.
- 2. Peptides1 Ovagen capsule product page
Supplier’s own instructions inspected:1–2 capsules1–2 times daily with meals,10–30 days. Disease and no-side-effect assertions not adopted.
- 3. Ovagen/EDL patent WO2007139430A1
Legacy 4.08 h remains an assumption; the patent has no verified plasma PK row used here.
- 4. Zamorskii et al. 2017 — EDL in rat kidney injury
Original gentamicin and ischemia/reperfusion rat kidney experiments; not a human liver or kidney efficacy trial.
Keep reading
Related compounds and examples
Related compounds
Epithalon (Epitalon)
Epithalon for sleep and longevity: reported dose ranges, Epithalamin confusion and why telomere changes do not prove longer life.
Chonluten
Chonluten is a short peptide often linked to lung-health research. A direct study found changes in inflammatory signals in laboratory immune cells; it did not test breathing or lung recovery in people.
Livagen
Livagen is a short peptide studied in liver tissue and isolated blood cells. The research describes changes in cell growth and DNA packaging, not a proven liver-detox or liver-repair treatment in people.